PharmID was founded in early 2017 to develop and commercialize technology developed by MarqMetrix for healthcare and pharmacy uses. MarqMetrix has been providing non-destructive quantitative and qualitative Raman Spectroscopy tools and services to industrial clients (petro- and agri-chemical, pharmaceutical and others) for the last 5+ years. Two of the founders of PharmID have family connections in pharmacy, so it was only a matter of time before the connection of Raman Spectroscopy to assist pharmacy in identification and verification of medications was made. PharmID is currently pursuing products to support drug diversion prevention, IV compounding verification and other activities where knowing for certain what-the-drug-is is important.

PharmID was founded in early 2017 to develop and commercialize technology developed by MarqMetrix for healthcare and pharmacy uses. MarqMetrix has been providing non-destructive quantitative and qualitative Raman Spectroscopy tools and services to industrial clients (petro- and agri-chemical, pharmaceutical and others) for the last 5+ years. Two of the founders of PharmID have family connections in pharmacy, so it was only a matter of time before the connection of Raman Spectroscopy to assist pharmacy in identification and verification of medications was made. PharmID is currently pursuing products to support drug diversion prevention, IV compounding verification and other activities where knowing for certain what-the-drug-is is important.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.